Lumiliximab
(Redirected from
Gomiliximab
)| Target | CD23 |
|---|---|
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C2115H3252N556O673S16 |
| Molar mass | 47749.46 g·mol−1 |
  (what is this?) (verify) | |
Lumiliximab is an IgG1k
orphan drug status and fast track designation by the FDA.[2]
It was investigated in Phase II/III
Homo sapiens.[1]
Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007.[2] Results published from the CLL clinical trial failed to meet primary endpoints.[5]
References
- ^ a b "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 18 (3). 2004.
- ^ a b "Lumiliximab". Adis Insight. Springer Nature Switzerland AG.
- PMID 19843887.
- ^ Clinical trial number NCT00801060 for "Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)" at ClinicalTrials.gov
- S2CID 25789983.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |